Inflammatory Bowel Disease: A Clinical Case Approach to Pathophysiology, Diagnosis, and TreatmentM. Campieri This book is the proceedings of the Falk Symposium No. 122 on "Inflammatory Bowel Disease - A Clinical Case Approach to Pathophysiology, Diagnosis, and Treatment", held in Bologna, Italy, on June 22-23, 2001, and deals with some major issues concerning Genetics of IBD, Pediatrics in IBD, Early vs Late IBD, Bacteria and Gut Inflammation, Refractory CD, Fistulizing CD, Refractory Distal Colitis, and Complications of Ileal-Pouch Anastomosis. The main aim of the meeting was to highlight the value of an integrated clinical approach and the importance of clinical research in developing innovative methods of treatment. |
Contents
Genetics of IBD case presentation | 3 |
Intestinal permeability in Crohns disease genetic environmental or inflammatory? | 7 |
Screening for IBD susceptibility subclinical markers | 17 |
Genetics of IBD chromosomal studies | 22 |
Defining clinical activity in Crohns disease | 32 |
Severe ulcerative colitis in a toddler a complicated course | 43 |
Paediatrics in IBD epidemiology and risk factors | 49 |
The diagnosis of paediatric inflammatory bowel disease | 53 |
Prevention and management of postoperative recurrence in Crohns disease | 173 |
Refractory Crohns disease discussion of the case | 181 |
Mechanisms of refractoriness in Crohns disease | 185 |
The traditional immunosuppressors | 201 |
Novel therapeutic options in Crohns disease targeting the MAP kinase pathways | 206 |
Refractory Crohns disease when is the time for surgery? | 214 |
Fistulizing CD a case report | 225 |
Fistulizing Crohns disease discussion of the case | 233 |
Growth failure in children with IBD | 65 |
Medical management of IBD children versus adults | 71 |
Nutrition therapy in inflammatory bowel disease | 85 |
Early versus late IBD clinical comments | 97 |
Early and late inflammatory bowel disease differential mechanisms | 103 |
Evolution into chronicity | 110 |
Ulcerative colitis and multiple organ dysfunction syndrome MODS | 115 |
Early versus late inflammatory bowel disease implications for therapy | 122 |
Cells of the intestinal mucosa from inflammation to fibrosis | 127 |
Bacteria and gut inflammation a case report | 145 |
Bacteria and gut inflammation | 148 |
Dietary components as antigens haptens and mitogens in the pathogenesis of inflammatory bowel disease | 153 |
Use of antibiotics and probiotics in Crohns disease | 158 |
Probiotics in IBD | 164 |
Fistulizing Crohns disease medical treatment | 239 |
Fistulizing Crohns disease | 245 |
Alternative therapies in inflammatory bowel disease | 256 |
Diagnostic and therapeutic challenges in indeterminate refractory colitis | 267 |
Indeterminate colitis | 274 |
IBD UC or CD | 278 |
The neuromodulation of intestinal inflammation | 294 |
Relationship between stress neuroimmune function and gut inflammation | 300 |
Medical therapy of ulcerative colitis | 306 |
Postoperative complications after ileal pouchanal anastomosis | 313 |
Complications of the ileoanal pouch medical complications | 329 |
Inflammatory bowel disease how does basic science help clinical management? | 335 |
343 | |
Common terms and phrases
5-aminosalicylic 6-mercaptopurine abdominal abscess acid active Crohn's disease acute anastomosis antibiotics antibodies antigens ASCA associated azathioprine bacteria biopsies budesonide CD patients cells chronic Clin clinical colon complications controlled trial corticosteroids Crohn's disease cyclosporine cytokines diagnosis diet disease activity dose drug effect efficacy endoscopic enteral nutrition epithelial experimental colitis factors families fibroblasts fistulas Gastroenterology gastrointestinal gene genetic growth failure histological ileal ileostomy ileum immune Immunol increased indeterminate colitis induced Inflamm Bowel inflammation inflammatory bowel disease infliximab intestinal inflammation intestinal permeability kinase lesions linkage long-term MAPK markers mediators mesalazine metronidazole mice models mucosal myofibroblasts onset oral p38 MAPK patients with Crohn's Pediatr Gastroenterol Nutr perianal placebo postoperative pouch pouchitis present probiotic protein rats recent rectal Rectum recurrence refractory relapse remission reported resection response risk role Rutgeerts small bowel steroids surgery surgical symptoms therapeutic therapy tion tissue treated ulcerative colitis